BioMarin Pharmaceutical Inc. (LON:0HNC)
London
· Delayed Price · Currency is GBP · Price in USD 58.73
+0.39 (0.66%)
At close: May 29, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| NAGLAZYME | 488.25M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| NAGLAZYME Growth | 21.18% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| ALDURAZYME | 197.60M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| ALDURAZYME Growth | 49.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| KUVAN | 110.13M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| KUVAN Growth | -33.74% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Net Product | 2.91B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Net Product Growth | 19.90% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| VIMIZIM | 735.61M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| VIMIZIM Growth | 4.43% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BRINEURA | 170.40M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BRINEURA Growth | 5.32% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| PALYNZIQ | 372.61M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| PALYNZIQ Growth | 17.44% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| VOXZOGO | 795.96M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| VOXZOGO Growth | 48.80% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| ROCTAVIAN | 35.73M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| ROCTAVIAN Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Royalty and Other | 43.95M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Royalty and Other Growth | -7.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States | 973.51M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Growth | 22.07% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe | 862.86M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Growth | 22.50% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Latin America | 387.77M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Latin America Growth | 12.96% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World Revenue (Pre-Q3 2024) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World Revenue (Pre-Q3 2024) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World Revenue (Post-Q2 2024) | 484.53M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World Revenue (Post-Q2 2024) Growth | 8.49% |
Log In |
Log In |
Log In |
Log In | Upgrade
|